Clin2
NCT02042326Possibly a fitRecruiting

Sirolimus trial for severe arteriovenous malformations

Arteriovenous Malformations

Treatments studied

Part of Genetic & congenital, Heart & circulation clinical trials.

This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
2 years and older
Study type
Interventional

Who can take part

  • You have an arteriovenous malformation (AVM) that is stage II/III or IV, active or not
  • You (or your parent/guardian) can understand the study and sign consent
  • If you can become pregnant, you must use reliable birth control during the study and for 12 weeks after
  • If you can become pregnant, your pregnancy test must be negative
  • You must be able to have MRI scans as part of the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07477548Not yet recruiting· Phase 2
Testing everolimus for stubborn vascular anomalies

This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.

NCT02638389Recruiting· Phase 3
Sirolimus for hard-to-treat vascular birthmarks

This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.

Brussels, Brussels Capital
NCT04861064Recruiting· Phase 2
Weekly sirolimus for blood and lymph vessel malformations

This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.

Charleston, South Carolina
NCT04141020Recruiting· Phase 2
Sirolimus study for unruptured brain aneurysms after surgery

This Phase 2 study tests whether sirolimus, a medicine that changes immune and growth signals, can change what’s happening inside the tissue of unruptured brain aneurysms after a procedure. Researchers hope these molecular changes may help understand how to improve aneurysm outcomes.

Miami, Florida
NCT06673290Recruiting· Phase 2/Phase 3
Testing different doses of sirolimus for cystic lymphatic malformations

This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.

Chengdu, Sichuan
NCT06091332Recruiting· Phase 2
Sirolimus for brainstem cavernoma bleeding

This trial tests if sirolimus, a medicine that may help reduce abnormal blood vessels, can prevent another brain bleed in people who recently had a bleed from a brainstem cavernoma. You would receive either sirolimus or a placebo to see if it works.

Shanghai, Shanghai Municipality

Hear when a new Arteriovenous Malformations trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.